Mutations at BRCA1: the medullary breast carcinoma revisited - PubMed (original) (raw)
. 1998 Apr 15;58(8):1588-92.
J Jacquemier, C Charpin, D Stoppa-Lyonnet, B Bressac-de Paillerets, J P Peyrat, M Longy, J M Guinebretière, R Sauvan, T Noguchi, D Birnbaum, H Sobol
Affiliations
- PMID: 9563465
Mutations at BRCA1: the medullary breast carcinoma revisited
F Eisinger et al. Cancer Res. 1998.
Abstract
BRCA1-associated breast cancers (BRCA1-BCs) frequently harbor a high histoprognostic grade, p53 alterations, and estrogen receptor negativity. Although these parameters predict a poor outlook, the overall survival in BRCA1-BCs is equivalent to or even better than that in sporadic cases. These features are reminiscent of what is observed for breast carcinoma of the medullary type, a high-grade tumor with a particular favorable course. To explore a possible relationship between this phenotype and BRCA1 mutations, we first compared 32 BRCA1-BCs and 200 consecutive cases of breast cancer without familial history for the prevalence of typical medullary breast carcinoma (TMC) using the criteria given by Ridolfi et al. [R. Ridolfi et al, Cancer (Phila.), 40: 1365-1385, 1977]. Second, we searched for BRCA1 mutations in a set of 18 cases of TMC, using denaturing gradient gel electrophoresis and Cleavase fragment length polymorphism scanning. Six of 32 (19%) BRCA1-BCs were of the TMC type, compared to 0 of 200 controls (P < 0.0001). Among the 18 TMCs, 2 BRCA1 nonsense mutations were found. This corresponds to almost 7 times the contribution of BRCA1 mutations in the general population. Two additional missense mutations were identified. Together, these results suggest that, although TMC and BRCA1-BCs are not strictly coincidental, an important connection between the two populations does exist.
Similar articles
- BRCA1 mutations and polymorphisms in a hospital-based consecutive series of breast cancer patients from Apulia, Italy.
Tommasi S, Crapolicchio A, Lacalamita R, Bruno M, Monaco A, Petroni S, Schittulli F, Longo S, Digennaro M, Calistri D, Mangia A, Paradiso A. Tommasi S, et al. Mutat Res. 2005 Oct 15;578(1-2):395-405. doi: 10.1016/j.mrfmmm.2005.06.010. Epub 2005 Jul 18. Mutat Res. 2005. PMID: 16026807 - The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2.
Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Futreal PA, Peto J, Stoppa-Lyonnet D, Bignon YJ, Stratton MR. Lakhani SR, et al. Clin Cancer Res. 2000 Mar;6(3):782-9. Clin Cancer Res. 2000. PMID: 10741697 - Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.
Lidereau R, Eisinger F, Champème MH, Noguès C, Bièche I, Birnbaum D, Pallud C, Jacquemier J, Sobol H. Lidereau R, et al. Cancer Res. 2000 Mar 1;60(5):1206-10. Cancer Res. 2000. PMID: 10728676 - The molecular pathology of hereditary breast cancer.
Palacios J, Robles-Frías MJ, Castilla MA, López-García MA, Benítez J. Palacios J, et al. Pathobiology. 2008;75(2):85-94. doi: 10.1159/000123846. Epub 2008 Jun 10. Pathobiology. 2008. PMID: 18544963 Review. - Histopathology of BRCA1- and BRCA2-associated breast cancer.
Honrado E, Benítez J, Palacios J. Honrado E, et al. Crit Rev Oncol Hematol. 2006 Jul;59(1):27-39. doi: 10.1016/j.critrevonc.2006.01.006. Epub 2006 Mar 10. Crit Rev Oncol Hematol. 2006. PMID: 16530420 Review.
Cited by
- Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams NO, Quiroga D, Johnson C, Brufsky A, Chambers M, Bhattacharya S, Patterson M, Sardesai SD, Stover D, Lustberg M, Noonan AM, Cherian M, Bystry DM, Hill KL, Chen M, Phelps MA, Grever M, Stephens JA, Ramaswamy B, Carson WE 3rd, Wesolowski R. Williams NO, et al. Ther Adv Med Oncol. 2023 Dec 25;15:17588359231217976. doi: 10.1177/17588359231217976. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38152697 Free PMC article. - Medullary breast carcinoma: a pathogenic review and immunohistochemical study using tissue microarray.
Lee M, Jara-Lazaro AR, Cheok PY, Thike AA. Lee M, et al. Singapore Med J. 2022 Jul;63(7):394-401. doi: 10.11622/smedj.2021031. Epub 2021 Apr 16. Singapore Med J. 2022. PMID: 33866710 Free PMC article. - Impact of BRCA Mutation Status on Tumor Infiltrating Lymphocytes (TILs), Response to Treatment, and Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy.
Grandal B, Evrevin C, Laas E, Jardin I, Rozette S, Laot L, Dumas E, Coussy F, Pierga JY, Brain E, Saule C, Stoppa-Lyonnet D, Frank S, Sénéchal C, Lae M, De Croze D, Bataillon G, Guerin J, Reyal F, Hamy AS. Grandal B, et al. Cancers (Basel). 2020 Dec 8;12(12):3681. doi: 10.3390/cancers12123681. Cancers (Basel). 2020. PMID: 33302444 Free PMC article. - Clinicopathological characteristics of BRCA-associated breast cancer in Asian patients.
Kim EK, Park SY, Kim SW. Kim EK, et al. J Pathol Transl Med. 2020 Jul;54(4):265-275. doi: 10.4132/jptm.2020.04.07. Epub 2020 May 14. J Pathol Transl Med. 2020. PMID: 32397691 Free PMC article. Review. - Breast cancer histologic subtypes show excess familial clustering.
Henry NL, Cannon-Albright LA. Henry NL, et al. Cancer. 2019 Sep 15;125(18):3131-3138. doi: 10.1002/cncr.32198. Epub 2019 May 23. Cancer. 2019. PMID: 31120568 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Research Materials
Miscellaneous